On January 13, 2025 Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, reported preliminary financial results for the fourth quarter and year-ended December 31, 2024 (Press release, Delcath Systems, JAN 13, 2025, View Source [SID1234649650]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Preliminary Fourth Quarter and Full-Year 2024 Financial Results (unaudited)

Total fourth quarter and full year revenue expected to be approximately $15.1 million and $37.2 million, respectively
HEPZATO KIT fourth quarter and full year revenue expected to be approximately $13.7 million and $32.3 million, respectively
CHEMOSAT fourth quarter and full year revenue expected to be approximately $1.4 million and $4.9 million, respectively
Gross margins expected to be in the 80%-85% range
As of December 31, 2024, the Company had approximately $53.2 million of cash, cash equivalents and short-term investments and no debt
Final financial results for the fourth quarter and full year 2024 and a detailed business update will be provided during Delcath’s annual financial results release and investor call scheduled for March 6, 2025.